This study provides strong evidence that UHMK1 contributes to PCa progression through a UHMK1/MTHFD2 positive feedback loop, suggesting that UHMK1 might be a potential biomarker and attractive therapeutic target for advanced PCa. Here, MTHFD2 is linked to posterior cortical atrophy.